{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:59:10Z","timestamp":1785812350174,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpagonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric and Adolescent Gynecology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jpag.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T23:31:07Z","timestamp":1615678267000},"page":"591-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["What the Pediatric and Adolescent Gynecology Clinician Needs to Know about Acne"],"prefix":"10.1016","volume":"34","author":[{"given":"Amanda","family":"Rusk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Lucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.jpag.2021.03.002_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.13190","article-title":"Understanding innate immunity and inflammation in acne: implications for management","volume":"29","author":"Dreno","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0002","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jaad.2019.01.092","article-title":"Acne vulgaris: what's new in our 40th year","volume":"82","author":"Harper","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0003","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.mce.2017.09.009","article-title":"Androgens and androgen receptor action in skin and hair follicles","volume":"465","author":"Ceruti","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00403-009-1019-6","article-title":"Effect of dihydrotestosterone on the upregulation of inflammatory cytokines in cultured sebocytes","volume":"302","author":"Lee","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jpag.2021.03.002_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1196\/annals.1315.009","article-title":"An update of congenital adrenal hyperplasia","volume":"1038","author":"New","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jpag.2021.03.002_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jdv.14374","article-title":"What is new in the pathophysiology of acne, an overview","volume":"31","author":"Dr\u00e9no","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s40168-018-0558-5","article-title":"Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris","volume":"6","author":"O'Neill","year":"2018","journal-title":"Microbiome"},{"key":"10.1016\/j.jpag.2021.03.002_bib0008","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1365-2133.2005.06933.x","article-title":"Induction of toll-like receptors by Propionibacterium acnes","volume":"153","author":"Jugeau","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0009","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000087011","article-title":"Review of the innate immune response in acne vulgaris: activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses","volume":"211","author":"Kim","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jpag.2021.03.002_bib0010","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaad.2019.08.078","article-title":"The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis","volume":"82","author":"Woo","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 3","key":"10.1016\/j.jpag.2021.03.002_bib0011","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2013-0490B","article-title":"Evidence-based recommendations for the diagnosis and treatment of pediatric acne","volume":"131","author":"Eichenfield","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpag.2021.03.002_bib0012","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1468-3083.2007.02497.x","article-title":"Acne: prevalence, perceptions and effects on psychological health among adolescents in Aydin, Turkey","volume":"22","author":"Uslu","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D34HP8N68P","article-title":"Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders","volume":"17","author":"Dunn","year":"2011","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jpag.2021.03.002_bib0014","first-page":"1","article-title":"Psychosocial impact of acne vulgaris: evaluating the evidence","volume":"9","author":"Tan","year":"2004","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jpag.2021.03.002_bib0015","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.3928\/19382359-20200211-01","article-title":"Acne vulgaris: treatment made easy for the primary care physician","volume":"49","author":"Berry","year":"2020","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.jpag.2021.03.002_bib0016","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-0560.1974.tb00628.x","article-title":"Studies on the mechanism of action of topical benzoyl peroxide and vitamin A acid in acne vulgaris","volume":"1","author":"Fulton","year":"1974","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0017","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.det.2018.12.001","article-title":"An overview of acne therapy, part 1: topical therapy, oral antibiotics, laser and light therapy, and dietary interventions","volume":"37","author":"Marson","year":"2019","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jpag.2021.03.002_bib0018","article-title":"Topical benzoyl peroxide for acne","volume":"3","author":"Yang","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpag.2021.03.002_bib0019","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/exd.13934","article-title":"Salicylic acid treats acne vulgaris by suppressing AMPK\/SREBP1 pathway in sebocytes","volume":"28","author":"Lu","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0020","first-page":"427","article-title":"The use of sulfur in dermatology","volume":"3","author":"Gupta","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0021","first-page":"964","article-title":"Azelaic acid: evidence-based update on mechanism of action and clinical application","volume":"14","author":"Schulte","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0022","first-page":"1","article-title":"A novel topical retinoid for acne: trifarotene 50 \u03bcg\/g cream","volume":"25","author":"Tan","year":"2020","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jpag.2021.03.002_bib0023","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1080\/09546634.2017.1309349","article-title":"Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects","volume":"28","author":"Khalil","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"suppl 6","key":"10.1016\/j.jpag.2021.03.002_bib0024","first-page":"s3","article-title":"Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris","volume":"7","author":"Thiboutot","year":"2008","journal-title":"J Drugs Dermatol"},{"issue":"suppl 6","key":"10.1016\/j.jpag.2021.03.002_bib0025","first-page":"s1","article-title":"Is switching retinoids a sound strategy for the treatment of acne vulgaris?","volume":"7","author":"Gold","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0026","first-page":"549","article-title":"Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgari","volume":"9","author":"Tanghetti","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"suppl 6","key":"10.1016\/j.jpag.2021.03.002_bib0027","first-page":"s18","article-title":"Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris","volume":"7","author":"Pariser","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0028","first-page":"650","article-title":"Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgari","volume":"8","author":"Kircik","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0029","doi-asserted-by":"crossref","first-page":"70","DOI":"10.36849\/JDD.2020.3977","article-title":"Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials","volume":"19","author":"Tanghetti","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0030","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0031","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaad.2018.09.055","article-title":"Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments","volume":"80","author":"Barbieri","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0032","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jaad.2019.04.012","article-title":"Changes in the management of acne: 2009-2019","volume":"82","author":"Thiboutot","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0033","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/jamadermatol.2013.6746","article-title":"High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris","volume":"149","author":"Blasiak","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0034","unstructured":"iPledge REMS [prescribing information]. Available: https:\/\/www.ipledgeprogram.com\/iPledgeUI\/prInfo.u . Accessed August 18, 2020"},{"key":"10.1016\/j.jpag.2021.03.002_bib0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaad.2019.06.025","article-title":"The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time","volume":"82","author":"Barbieri","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0036","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","article-title":"Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials","volume":"156","author":"Hebert","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0037","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0010-7824(99)00093-1","article-title":"Effect of low-dose oral contraceptives on androgenic markers and acne","volume":"60","author":"Thorneycroft","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.jpag.2021.03.002_bib0038","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/11535450-000000000-00000","article-title":"Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women","volume":"30","author":"Kelly","year":"2010","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jpag.2021.03.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004425.pub5","article-title":"Combined oral contraceptive pills for treatment of acne","volume":"7","author":"Arowojolu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpag.2021.03.002_bib0040","unstructured":"FDA. US Food and Drug Administration: MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available: www.fda.gov\/medwatch. Accessed August 18, 2020"},{"key":"10.1016\/j.jpag.2021.03.002_bib0041","unstructured":"FDA. US Food and Drug Administration: ESTROSTEP Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets*) package insert. Irvine, CA: Allergan Inc.; Revised 2017. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020130s018lbl.pdf. Accessed April 1, 2021."},{"key":"10.1016\/j.jpag.2021.03.002_bib0042","unstructured":"FDA. US Food and Drug Administration: YAZ \u00ae (Drospirenone and Ethinyl Estradiol) Tablets package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; Revised 2012. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021676s012lbl.pdf. Accessed April 1, 2021."},{"key":"10.1016\/j.jpag.2021.03.002_bib0043","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0029-7844(97)00059-8","article-title":"Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial","volume":"89","author":"Redmond","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0044","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","article-title":"Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial","volume":"112","author":"Maloney","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0045","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/1523-1747.ep12472325","article-title":"Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5\u03b1-dihydrotestosterone in vitro","volume":"100","author":"Akamatsu","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0046","first-page":"632","article-title":"Frequency of treatment switching for spironolactone compared to oral tetracycline-class antibiotics for women with acne: a retrospective cohort study 2010-2016","volume":"17","author":"Barbieri","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0047","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40257-018-0349-6","article-title":"The use of hormonal antiandrogen therapy in female patients with acne: a 10-year retrospective study","volume":"19","author":"Park","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0048","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1684\/ejd.2017.3062","article-title":"Adult female acne treated with spironolactone: a retrospective data review of 70 cases","volume":"27","author":"Isvy-Joubert","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0049","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/jdv.16302","article-title":"Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017","volume":"34","author":"Roberts","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","volume":"151","author":"Plovanich","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0051","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40257-020-00511-5","article-title":"Oral spironolactone for acne vulgaris in adult females: an update of the literature","volume":"21","author":"Barker","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0052","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaad.2018.10.023","article-title":"Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review","volume":"80","author":"Liszewski","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0053","unstructured":"Pfizer: Aldactone package insert. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/012151s062lbl.pdf . Accessed August 18, 2020"},{"key":"10.1016\/j.jpag.2021.03.002_bib0054","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1046\/j.1365-4362.2003.01611.x","article-title":"Factors related to patient compliance in the treatment of acne vulgaris","volume":"42","author":"McEvoy","year":"2003","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0055","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1097\/DSS.0000000000000746","article-title":"Acne scar treatment: a multimodality approach tailored to scar type","volume":"42","author":"Zaleski-Larsen","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jpag.2021.03.002_bib0056","first-page":"586","article-title":"Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study","volume":"10","author":"Kircik","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0057","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/DSS.0000000000001765","article-title":"A review and update of treatment options using the Acne Scar Classification System","volume":"45","author":"Boen","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jpag.2021.03.002_bib0058","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/jocd.13556","article-title":"Chemical reconstruction of skin scars (CROSS) method for atrophic scars: a comprehensive review","volume":"20","author":"Chung","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jpag.2021.03.002_bib0059","first-page":"21","article-title":"Update on acne scar treatment","volume":"102","author":"Soliman","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.jpag.2021.03.002_bib0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-0037-1606096","article-title":"Ablative fractional CO 2 laser for facial atrophic acne scars","volume":"34","author":"Xu","year":"2018","journal-title":"Facial Plast Surg"}],"container-title":["Journal of Pediatric and Adolescent Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083318821001522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083318821001522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:48:49Z","timestamp":1761054529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083318821001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1083318821001522"],"URL":"https:\/\/doi.org\/10.1016\/j.jpag.2021.03.002","relation":{},"ISSN":["1083-3188"],"issn-type":[{"value":"1083-3188","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What the Pediatric and Adolescent Gynecology Clinician Needs to Know about Acne","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric and Adolescent Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpag.2021.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 North American Society for Pediatric and Adolescent Gynecology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}